nano carriers

1. S . VENKATESH

2. INTRODUCTION
A nanocarrier is nanomaterial being used as a transport module for
another substance, such as a drug.
 Commonly used nanocarriers include micelles, polymers, carbon-
based materials, liposomes and other substances.
 Nanocarriers are currently being studied for their use in drug delivery
and their unique characteristics demonstrate potential use in
chemotherapy.
UPAC definition
Particle of any shape with dimensions in the 1 × 10−9
and 1 × 10−7
m
range.

3. ORIGIN
Although, in general, nanoparticles are considered a
discovery of modern science, they actually have a long
history.
Nanoparticles were used by artisans as far back as the
ninth century in Mesopotamia for generating a glittering
effect on the surface of pots.
Michael Faraday provided the first description, in
scientific terms, of the optical properties of nanometer-
scale metals in his classic 1857 paper.

4. TYPES OF NANO CARRIERS

5. RATIONAL USE OF NANO CARRIRERS

6. MECHANISM

7. EXAMPLES OF NANO BASED PLATFORMS AND THEIR CURRENT STAGE OF DEVELOPMENT FOR THE
USE IN CANCER THERAPY

8. CONCLUSION
The clinical success of various nano carrier
constructs in cancer therapy have made these and
similar systems promising drug delivery vehicles
for future work aimed to further improve their
overall drug delivery efficacy . for example, the
clinical success based on passively delivering
chemotherapeutics encapsulated within both
liposomes and micelles in cancer treatment have
made these nano carriers particularly attractive
candidates for future work involving a more active
form of delivery

9. REFERENCES
 1.)https://en.wikipedia.org/wiki/Nanocarriers
 2.) Nanocarriers in modern drug delivery systems Katarzyna NIEMIROWICZ, Halina CAR – Department of
Experimental Pharmacology, Medical University of Bialystok, Białyst, CHEMIK 2012, 66, 8, 868-881
 3.)Dan Peer1†, Jeffrey M. Karp2,3†,Seungpyo Hong4†, Omid C. Farokhzad5,Rimona Margalit6 and Robert
Langer3,4*1Immune Disease Institute and Department of Anesthesia, Harvard MedicalSchool, Boston, Massachusetts
02115, USA; 2HST Center for BiomedicalEngineering, Department of Medicine, Brigham and Women’s Hospital,
HarvardMedical School, Cambridge, Massachusetts 02139, USA; 3Harvard-MIT Divisionof Health Sciences and
Technology, Massachusetts Institute of Technology,Cambridge, Massachusetts 02139, USA; 4Department of Chemical
Engineering,Massachusetts Institute of Technology, Cambridge, Massachusetts 02139,USA; 5Laboratory of
Nanomedicine and Biomaterials and Department ofAnesthesiology, Brigham and Women’s Hospital, Harvard Medical
School,Boston, Massachusetts 02115, USA; 6Department of Biochemistry, GeorgeS. Wise Faculty of Life Sciences, and
the Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 69978, Israel, Nanocarriers as an
emerging platform for cancer therapy
 4.)http://ec.europa.eu/health/scientific_committees/opinions_layman/en/nanotechnologies/l-3/4-nanoparticle-
formation.htm
 5.)https://en.wikipedia.org/wiki/Nanoparticle
 6.)https://en.wikipedia.org/wiki/Nanoparticle